Liver transplantation as treatment for neurological disorders

Expert Review of Neurotherapeutics

Volumn 3, Issue 4, 2003, Pages 547-555

  Ikeda, Shu Ichi ^a   Takei, Yo Ichi ^a   Hashikura, Yasuhiko ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Amyliod neuropathy; Hepatic encephalopathy; Hyperammonemia; Liver transplantation; Transthyretin; Urea cycle disorders

Indexed keywords

AMMONIA; ARGININOSUCCINATE SYNTHASE; CITRULLINE; PREALBUMIN;

CITRULLINEMIA; DISEASE COURSE; ENZYME ACTIVITY; FAMILIAL AMYLOID POLYNEUROPATHY; HUMAN; LIVER TRANSPLANTATION; LIVING DONOR; NEUROLOGIC DISEASE; PATHOGENESIS; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0037700913     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.3.4.547     Document Type: Review

References (79)

1. Mowat AP. Orthotopic liver transplantation in liver based metabolic disorders. Eur. J. Pediatr. 151(Suppl. 1), S32-S38 (1992).
2. Kaneko K, Takei Y, Aoki T, Ikeda S, Matsunami H, Lynch S. Bilirubin adsorption therapy and subsequent liver transplantation cured severe bilirubin encephalopathy in a long-term survival patient with Criglerq-Najjar disease type I. Intern. Med. 39, 961-965 (2000).
3. Ikeda S, Hanyu N, Hongo M et al. Hereditary generalized amyloidosis with polyneuropathy. Clinicopathological study of 65 Japanese patients. Brain 110, 315-337 (1987).
4. Andrade C. A peculiar form of peripheral neuropathy: familial atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 110, 408-427 (1952).
5. Andersson R. Familial amyloidosis with polyneuropathy. Acta Med. Scand. 188, 85-94 (1970).
6. Araki S, Mawatari S, Ohta M, Nakajima A, Kuroiwa Y. Polyneuritic amyloidosis in a Japanese family. Arch. Neurol. 18, 593-602 (1968).
7. Kito S, Itoga E, Kamiya K, Kishida T, Yamamura Y. Studies on familial amyloid polyneuropathy in Ogawa village, Japan. Eur. Neurol. 19, 141-151 (1980).
8. Connors LH, Richardson AM, Théberge R, Costello CE. Tabulation of transthyretin (TTR) variants as of 1/1/2000. Amyloid. Int. J. Exp. Clin. Invest. 7, 54-69 (2000).
9. Nakazato M, Kangawa K, Minamino N, Tawara S, Matsuo H, Araki S. Radioimmunoassay for detecting abnormal prealbumin in the serum for diagnosis of familial amyloidotic polyneuropathy (Japanese type). Biochem. Biophys. Res. Commu. 122, 719-725 (1984).
10. Ikeda S, Nakano T, Yanagisawa N, Nakazato M, Tsukagoshi H. Asymptomatic homozygous gene carrier in a family with type I familial amyloid polyneuropathy. Eur. Neurol 32, 308-313 (1992).
11. Tachibana N, Tokuda T, Yoshida K et al. Usefulness of MALDI/TOF mass spectrometry of immunoprecipitated serum variant transthyretin in the diagnosis of familial amyloid polyneuropathy. Amyloid: Int. J. Exp. Clin. Invest. 6, 282-288 (1999).
12. Ikeda S, Nakazato M, Ando Y, Sobue G. Familial transthyretin-type amyloid polyneuropathy in Japan. Clinical and genetic heterogeneity. Neurology 58, 1001-1007 (2002). Describes the detailed clinical pictures of familial amyloid polyneuropathy including the widespread clinical variations.
13. Misu K, Hattori N, Nagamatsu M et al. Late-onset familial amyloid polyneuropathy type I (transthyretin Met 30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan. Clinicopathological and genetic features. Brain 122, 1951-1962 (1999).
14. Hattori T, Takei Y, Koyama J, Nakazato M, Ikeda S. Clinical and pathological studies of cardiac amyloidosis in transthyretin familial type amyloid polyneuropathy. Amyloid J. Protein Folding Disord. (In Press).
15. Takahashi K, Sakashita N, Ando Y, Suga M, Ando M. Late onset type I familial amyloidotic polyneuropathy: presentation of three autopsy cases in comparison with 19 autopsy cases of the ordinary type. Pathol. Int. 47, 353-359 (1997).
16. Nakamura Y, Yutani C, Nakazato M, Date Y, Baba T, Goto Y. A case of hereditary amyloidosis transthyretin variant Met 30 with amyloid cardiomyopathy, less polyneuropathy and the presence of giant cells. Pathol. Int. 49, 898-902 (1999).
17. Lobato L, Beirao I, Guimaraes SM et al. Familial amyloid polyneuropathy type I (Portuguese): distribution and characterization of renal amyloid deposits. Am. J. Kidney Dis. 31, 940-946 (1998).
18. Garzuly F, Wisniewski T, Brirrig F, Budka H. Familial meningocerebrovascular amyloidosis, Hungarian type, with mutant transthyretin (TTR Asp 18Gly). Neurology 47, 1562-1567 (1996).
19. Petersen RB, Goren H, Cohen M et al. Transthyretin amyloidosis: a new mutation associated with dementia. Ann. Neurol. 41, 307-313 (1997).
20. Uemichi T, Uitti RJ, Koeppen AH, Donat JR, Benson MD. Oculoleptomeningeal amyloidosis associated with a new transthyretin variant Ser64. Arch. Neurol. 56, 1152-1155 (1999).
21. Soprano DR, Herhert J, Soprano K, Schon E, Goodman D. Demonstration of transthyretin mRNA in the brain and other extrahepatic tissues. J. Biol. Chem. 260, 11793-11798 (1985).
22. 30). Clin. Genet. 40, 242-246 (1991).
23. Holmgren G, Ericzon B-G, Groth C-G et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 341, 1113-1116 (1993).
24. Ericzon B-G. Familial Amyloidotic Polyneuropathy World Transplant Register (FAPWTR) and the Domino Transplant Register. Update on behalf of reporting members of the FAPWTR December (2001).
25. Carvalho M de, Conceicao I, Bentes C, Luis MLS. Long-term quantitative evaluation of liver transplantation in familial amyloid polyneuropathy (Portuguese V30M). Amyloid: J. Protein Folding Disord. 9, 126-133 (2002).
26. Suhr OB, Holmgren G, Steen L et al. Liver transplantation in familial amyloidotic polyneuropathy. Transplantation 60, 933-938 (1995).
27. Bergethon PR, Sabin TD, Lewis D, Simms RW, Cohen AS, Skinner M. Improvement in the polyneuropathy associated with familial amyloid polyneuropathy after liver transplnatation. Neurology 47, 944-951 (1996).
28. Suhr OB, Wiklund U, Ando Y, Olofsson B-O. Impact of liver transplantation on autonomic neuropathy in familial amyloidotic polyneuropathy: an evaluation by spectral analysis of heart rate variability. J. Int. Med. 242, 225-229 (1997).
29. Adams D, Samuel D, Goulon-Goeau C et al. The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. Brain 123, 1495-1504 (2000). Describes therapeutic effects of liver transplantations for familial amyloid polyneuropathy patients by analyzing many parameters and also proposes the indication for liver transplantation in patients with this disease.
30. Jonsén E, Suhr OB, Tashima K, Athlin E. Early liver transplantation is essential for familial amyloidotic polyneuropathy patients' quality of life. Amyloid: J. Protein Folding Disord 8, 52-57 (2001).
31. Matsunami H, Makuuchi M, Kawasaki S et al. A case of familial amyloid polyneuroapthy treated with partial liver transplantation using a graft from a living related donor. Transplantation 60, 301-303 (1995).
32. Ikeda S, Takei Y, Yanagisawa N et al. Partial liver transplantation from living donors in familial amyloid polyneuropathy. Amyloid: Int. J. Exp. Clin. Invest. 4, 18-23 (1997).
33. Ikegami T, Kawasaki S, Ohno Y et al. Temporary auxiliary liver transplantation from a living donor to an adult recipient with familial amyloid polyneuropathy. Transplantion 73, 628-630 (2002).
34. Takei Y, Ikeda S, Hashikura Y, Ikegami T, Kawasaki S. Partial-liver transplantation to treat familial amyloid polyneuropathy: follow-up of 11 patients. Ann. Intern. Med. 131, 592-595 (1999).
35. Kobayashi S, Morita H, Asawa T et al. Peripheral nerve function in patients with familial amyloid polyneuropathy after liver transplantation. Amyloid: J. Protein Folding Disord. 10, 17-24 (2003).
36. Owa M, Takei Y, Hashikura Y, Kawasaki S, Koyama M, Ikeda S. Recurrent cerebral embolism in a familial amyloid polyneuropathy patient who received partial liver transplantation from a living donor. Intern. Med. 40, 259-264 (2001).
37. Suhr OB, Ericzon B-G, Friman S. Long-term follow-up of survival of liver transplant recipients with familial amyloid polyneuropathy (Portuguese type). Liver Transpl. 8, 787-794 (2002).
38. Ando Y, Ando E, Tanaka Y et al. De novo amyloid synthesis in ocular tissue in familial amyloidotic polyneuropathy after liver transplantation. Transplantation 82, 1097-1098 (1996).
39. Munar-Qués M, Salva-Ladaria L, Mulet-Perera P, Sole M, Lopez-Andreu FR, Saraiva MJM. Vitreous amyloidosis after liver transplantation in patients with familial amyloid polyneuropathy: ocular synthesis of mutant transthyretin. Amyloid: Int. J. Exp. Clin. Invest. 7, 266-269 (2000).
40. Haraoka K, Ando Y, Ando E et al. Presence of variant transthyretin in aqueous humor of a patient with familial amyloidotic polyneuropathy after liver transplantation. Amyloid: J. Protein Folding Disord. 9, 247-251 (2002).
41. Dubrey SW, Davidoff R, Skinner M, Bergethon P, Lewis D, Falk RH. Progression of ventricular wall thickening after liver transplantation for familial amyloidosis. Transplantation 64, 74-80 (1997).
42. Stangou AJ, Hawkins PN, Heaton ND et al. Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy. Transplantation 66, 229-233 (1998).
43. Olofsson B-O, Backman C, Karp K, Suhr OB. Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type. Transplantation 73, 745-751 (2002).
44. Westermark P, Sletten K, Johansson B, Cornwell GG. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc. Natl. Acad. Sci. USA 87, 2843-2845 (1990).
45. Yazaki M, Tokuda T, Nakamura A et al. Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wild type transthyretin. Biochem. Biophys. Res. Commun. 274, 702-706 (2000).
46. Brusilow SW, Horwich AL. Urea cycle enzymes. In: The Metabolic and Molecular Bases of Inherited Disease, 7th Edition. Scriver CR, Beaudet AL, Sly WS, Valle D (Eds). McGraw-Hill, NY, USA, 1187-1232 (1995).
47. Saheki T, Kobayashi K, Inoue I. Hereditary disorders of the urea cycle in man: biochemical and molecular approaches. Rev. Physiol. Biochem. Pharmacol. 108, 21-68 (1987a).
48. Ikeda S, Yazaki M, Takei Y et al. Type II (adult onset) citrullinemia: clinical pictures and the therapeutic effect of liver transplantation. J. Neurol. Neurosurg. Psychiatry 71, 663-670 (2001). First report that describes the detailed clinical pictures and therapeutic effect of liver transplantation in type II (adult onset) citrullinemia.
49. Shiraki H, Yamamoto T, Yamada K, Shikata T. An autopsied case of the 'pseudoulegyria type' of the hepatocerebral disease. Seishinshinkeishi 64, 305-318 (1962). (In Japanese)
50. Oda M. Ein Beitrag zu den klinischen und histopathologischen Problemen uber die hepatozerebralen Erkrankungen, isbesondere uber den 'Pseudoulegyrie Typ'. Seishinshinkeishi 65, 892-931 (1964). (In Japanese)
51. Shiraki H, Oda M. Pseudoulegyric type of hepatocerebral disease. Naika 28, 491-498 (1971). (In Japanese)
52. Tsuji T, Morita T, Matsuyama Y, Matsui T, Tamura M, Matsuoka Y. Sibling cases of chronic recurrent hepatocerebral disease with hypercitrullinemia. Gastroenterologia Japonica 11, 328-340 (1976).
53. Saheki T, Ueda A, Hosoya M et al. Qualitative and quantitative abnormalities of argininosuccinate synthetase in citrullinemia. Clin. Chim. Acta. 109, 325-335 (1981).
54. Saheki T, Ueda A, Hosoya M, Sase M, Nakano K, Katsunuma T. Enzymatic analysis of citrullinemia (12 cases) in Japan. Adv. Exp. Med. Biol. 153, 63-76 (1982).
55. Tomomasa T, Kobayashi K, Kaneko H et al. Possible clinical and histologic manifestations of adult-onset type II citrullinemia in early infancy. J. Pediatr. 138, 741-743 (2001).
56. Tazawa Y, Kobayashi K, Ohura T et al. Infantile cholestatic jaundice associated with adult-onset type II citrullinemia. J. Pediatr. 138, 735-740 (2001).
57. Saheki T, Kobayashi K. Mitochondrial aspartate glutamate carrier (citrin) deficiency as the cause of adult-onset type II citrullinemia (CTLN2) and idiopathic neonatal hepatitis (NICCD). J. Hum. Genet. 47, 333-341 (2002).
58. Kobayashi K, Jackson MJ, Tick DB, O'Brien WE, Beaudet AL. Heterogeneity of mutations in argininosuccinate synthetase causing human citrullinemia. J. Biol. Chem. 265, 11361-11367 (1990).
59. Kobayashi K, Shaheen N, Terazono H, Saheki T. Mutations in argininosuccinate synthetase mRNA of Japanese patients, causing classical citrullinemia. Am. J. Hum. Genet. 55, 1103-1112 (1994).
60. Kobayashi K, Shaheen N, Kumashiro R et al. A search for the primary abnormality in adult-onset type II citrullinemia. Am. J. Hum. Genet. 53, 1024-1030 (1993).
61. Kobayashi K, Sinasac DS, Iijima M et al. The gene mutated in adult-onset type II citrullinemia encodes a putative mitochondrial carrier protein. Nature Genet. 22, 159-163 (1999).
62. Yasuda T, Yamaguchi N, Kobayashi K et al. Identification of two novel mutations in the SLC25A13 gene and detection of seven mutations in 102 patients with adult-onset type II citrullinemia. Hum. Genet. 107, 537-545 (2000).
63. 2+-stimulated aspartate/glutamate transporters in mitochondria. EMBO J. 20, 5060-5069 (2001).
64. Takenaka K, Yasuda I, Araki H et al. Type II citrullinemia in an elderly patient treated with living related partial liver transplantation. Intern. Med. 39, 553-558 (2000).
65. 3 level in a case of sudden onset and rapidly progressive case of type II citrullineimia. Internal. Med. 39, 925-929 (2000).
66. Kobayashi K, Iijima M, Yasuda T et al. Type II Citrullinemia (citrin deficiency): a mysterious disease caused by a defect of calcium-binding mitochondrial carrier protein. In: Calcium: The Molecular Basis of Calcium Action in Biology and Medicine. Pochet R, Donato R, Haiech J, Heizmann C, Gerke V (Eds). Kluwer, The Netherlands, 565-587 (2000).
67. Imamura Y, Kobayashi K, Shibatou T et al. Effectiveness of carbohydrate-restricted diet and arginine granules therapy for adult-onset type II citrullinemia: a case report of siblings showing homozygous SLC25A13 mutation with and without the disease. Hepatol. Res. 26, 68-72 (2003).
68. Ito T, Shiraki K, Sekoguchi K et al. Hepatocellular carcinoma associated with adult-type citrullinemia. Digest. Dis. Sci. 45, 2203-2206 (2000).
69. Saheki T, Kobayashi K, Ichiki H et al. Molecular basis of enzyme abnormalities in urea cycle disorders: with special reference to citrullinemia and argininosuccinic aciduria. Enzyme 38, 227-232 (1987b).
70. Kobayashi T, Nakata M, Terazono H, Shinsato T, Saheki T. Pancreatic secretory trypsin inhibitor gene is highly expressed in the liver of adult-onset type II citrullinemia. FEBS Lett. 372, 69-73 (1995).
71. Kobayashi K, Horiuchi M, Saheki T. Pancreatic secretory trypsin inhibitor as a diagnostic marker for adult-onset type II citrullinemia. Hepatology. 25, 1160-1165 (1997).
72. Largilliere C, Houssin D, Gottrand F et al. Liver transplantation for ornithine transcarbamylase deficiency in a girl. Paediatrics 115, 415-417 (1989).
73. Mowat AP. Orthotopic liver transplantation in liver-based metabolic disorders. Eur. J. Pediatr. 151(Suppl. 1) S32-S38 (1992).
74. Jan D, Poggi F, Jouvet P et al. Definitive cure of hyperammonemia by liver transplantation in urea cycle defects: report of three cases. Transplant Proc. 26, 188 (1994).
75. Saudubray JM, Touati G, Delonlay P et al. Liver transplantation in urea cycle disorders. Eur. J. Pediatr. 158(Suppl. 2), S55-S59 (1999).
76. Todo S, Starzl TE, Tzakis A et al. Orthotopic liver transplantation for urea cycle enzyme deficiency. Hepatology 15, 419-422 (1992).
77. Yazaki M, Ikeda S, Takei Y et al. Complete neurological recovery of an adult patient with type II citrullinemia after living related partial liver transplantation. Transplantation 62, 1679-1681 (1996).
78. Kawamoto S, Strong RW, Kerlin P et al. Orthotopic liver transplantation for adult-onset type II citrullinemia. Clin. Transplantation 11, 453-458 (1997).
79. Kasahara M, Ohwada S, Takeichi T et al. Living-related liver transplantation for type II citrullinemia using a graft from heterozygote donor. Transplantation 71, 157-159 (2001).